Primary vaccine group | ||||
---|---|---|---|---|
AS03A-H5N1 | Non-adjuvanted-H5N1 | |||
N = 954† | N = 245† | |||
Heterologous booster group per-protocol immunogenicity cohort | ||||
Month 6 | Month 12 | Month 36 | Month 6 | |
N = 256 | N = 186 | N = 387 | N = 229 | |
Mean age, years | 33.3 | 35.4 | 38.0 | 33.5 |
(SD, range) | (10.16; 19–58) | (9.24; 21–59) | (9.74; 21–62) | (9.17; 19–58) |
Male, n (%) | 117 (45.7) | 89 (48.4) | 201 (51.9) | 115 (50.2) |
Female, n (%) | 139 (54.3) | 95 (51.6) | 186 (48.1) | 114 (49.8) |
Central/South Asian Heritage | 1 (0.4) | 2 (1.1) | 3 (0.8) | 5 (2.2) |
East Asian Heritage | 154 (60.2) | 115 (62.5) | 225 (58.1) | 135 (59.0) |
South East Asian heritage | 101 (39.5) | 66 (35.9) | 159 (41.1) | 88 (38.4) |
Arabic/North African Heritage | – | – | – | 1 (0.4) |